Key result
Acetylsalicylic acid monotherapy was associated with a higher risk of ischaemic stroke and thrombo-embolic events compared with no antithrombotic treatment in patients with atrial fibrillation.
Why the study?
Does acetylsalicylic acid monotherapy prevent stroke and thrombo-embolic events in patients with atrial fibrillation?
Cohort (n=115,185)
Yes
Does acetylsalicylic acid monotherapy prevent stroke and thrombo-embolic events in patients with atrial fibrillation?
Acetylsalicylic acid monotherapy offers no protective effect against stroke in atrial fibrillation and may increase risk, supporting guidelines against its use.
No takes yet. Share an insight, caveat, or question.
May increase stroke risk with aspirin monotherapy in AF; leaves open causal confirmation before practice change.
Själander et al. (2013) conducted a cohort in Atrial fibrillation (n=115,185). Acetylsalicylic acid (ASA) monotherapy vs. No antithrombotic treatment was evaluated on Ischaemic stroke, thrombo-embolic event, intracranial haemorrhage, and major bleeding. Acetylsalicylic acid monotherapy was associated with a higher risk of ischaemic stroke and thrombo-embolic events compared with no antithrombotic treatment in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: